Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design

Tao Wang, Chengyong Wu, Chengdi Wang, Guiping Zhang, Kinsie E. Arnst, Yijun Yao, Zhixiong Zhang, Yuxi Wang, Dan Pu, Weimin Li